News

Italian review of 11 studies of the use of the Anti-IgE medicine Omalizumab in oral immunotherapy (OIT) – Pharmaceuticals 2025 Mar 20;18(3):437. 3 studies looked at peanut allergy. Schneider’s study looked at 13 children aged 8-16. On the first day of OIT, all passed a 500mg dose of peanut flour! Within 8 weeks, all but… Read more: Systematic Review of Omalizumab and OIT

Helen Brough et al review the use of the Anti-IgE antibody to improve outcomes in oral immunotherapy (OIT). [J Allergy Clin Immunol Pract 2025 Apr;13(4):731-739] To begin with though, they review data on early life (pre-school) OIT. They suggest adherence is better, which I’m not convinced about, but point out that if you start early, you… Read more: Omalizumab and early life OIT

Article from Australia – remission is defined as being able to discontinue treatment for at least 8 weeks and still not have any reaction to peanut. This was a group of 162 children treated between the ages of 1 and 10 with peanut flour +/-probiotics, not Palforzia. The higher your peanut blood IgE level is… Read more: Predicting remission

Study from Canada – 69 children under the age of 3 reached maintenance dose of peanut over a median of 29 weeks (so slightly more than 6 months, on average). One patient had a peanut ingestion-related emergency department (ED) visit requiring adrenaline during initial dose escalation (first day). During the first year of maintenance phase, no… Read more: Safety of peanut OIT in young children in a clinic setting

Not a problem. We can “coast” on the same dose for as long as necessary. We would just continue with updoing when you get back. You would take the usual precautions around your allergies, with regards to informing your insurer, the airline, your accommodation. You can still message us if there are any issues. We… Read more: What if we want to go on holiday?